Concepts (201)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| DNA Methylation | 17 | 2023 | 301 | 5.050 |
Why?
|
| Prostatic Neoplasms | 27 | 2023 | 794 | 4.440 |
Why?
|
| Gene Expression Regulation, Neoplastic | 12 | 2023 | 781 | 2.350 |
Why?
|
| Prostate | 8 | 2023 | 136 | 1.030 |
Why?
|
| Histone-Lysine N-Methyltransferase | 2 | 2023 | 25 | 0.990 |
Why?
|
| Epigenesis, Genetic | 4 | 2020 | 198 | 0.970 |
Why?
|
| Crocus | 1 | 2023 | 16 | 0.950 |
Why?
|
| Phosphoproteins | 3 | 2011 | 154 | 0.920 |
Why?
|
| Biological Products | 1 | 2023 | 67 | 0.870 |
Why?
|
| Membrane Proteins | 5 | 2012 | 486 | 0.860 |
Why?
|
| Hydrocortisone | 1 | 2022 | 72 | 0.840 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2020 | 7 | 0.760 |
Why?
|
| Androgens | 1 | 2020 | 87 | 0.720 |
Why?
|
| CpG Islands | 8 | 2023 | 91 | 0.690 |
Why?
|
| Male | 30 | 2023 | 18870 | 0.660 |
Why?
|
| Promoter Regions, Genetic | 8 | 2018 | 484 | 0.610 |
Why?
|
| Cell Line, Tumor | 12 | 2020 | 2128 | 0.610 |
Why?
|
| Tumor Suppressor Proteins | 4 | 2018 | 184 | 0.590 |
Why?
|
| Cytokines | 2 | 2018 | 569 | 0.570 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2016 | 50 | 0.570 |
Why?
|
| Fibroblast Growth Factors | 6 | 2006 | 34 | 0.550 |
Why?
|
| Receptors, Fibroblast Growth Factor | 4 | 2004 | 10 | 0.540 |
Why?
|
| Healthcare Disparities | 1 | 2019 | 446 | 0.520 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 2 | 2013 | 13 | 0.520 |
Why?
|
| Humans | 34 | 2023 | 34853 | 0.520 |
Why?
|
| Gene Silencing | 4 | 2011 | 143 | 0.500 |
Why?
|
| Gene Expression Profiling | 3 | 2023 | 600 | 0.450 |
Why?
|
| Nerve Tissue Proteins | 2 | 2023 | 338 | 0.440 |
Why?
|
| Inflammation | 1 | 2016 | 577 | 0.420 |
Why?
|
| RNA, Messenger | 6 | 2023 | 1152 | 0.400 |
Why?
|
| Transcription Factors | 3 | 2011 | 653 | 0.400 |
Why?
|
| Phosphoric Monoester Hydrolases | 2 | 2001 | 33 | 0.390 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2001 | 58 | 0.390 |
Why?
|
| DNA-Binding Proteins | 4 | 2023 | 522 | 0.380 |
Why?
|
| Genes | 1 | 2010 | 58 | 0.380 |
Why?
|
| Receptors, Retinoic Acid | 3 | 2018 | 25 | 0.370 |
Why?
|
| Homeodomain Proteins | 1 | 2010 | 128 | 0.350 |
Why?
|
| Sequence Analysis, DNA | 5 | 2013 | 455 | 0.340 |
Why?
|
| Transcription, Genetic | 1 | 2011 | 550 | 0.330 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 8 | 2010 | 605 | 0.300 |
Why?
|
| Aged | 6 | 2019 | 6448 | 0.290 |
Why?
|
| Case-Control Studies | 2 | 2019 | 1056 | 0.280 |
Why?
|
| Alternative Splicing | 2 | 2009 | 82 | 0.280 |
Why?
|
| Adult | 7 | 2022 | 11034 | 0.270 |
Why?
|
| Cadherins | 2 | 2018 | 82 | 0.270 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-3 | 2 | 2018 | 9 | 0.270 |
Why?
|
| Osteonectin | 2 | 2018 | 7 | 0.270 |
Why?
|
| Azacitidine | 2 | 2016 | 21 | 0.270 |
Why?
|
| Receptors, Androgen | 2 | 2020 | 122 | 0.260 |
Why?
|
| Breast Neoplasms | 3 | 2012 | 1426 | 0.250 |
Why?
|
| Middle Aged | 6 | 2019 | 9642 | 0.250 |
Why?
|
| Emetine | 2 | 2015 | 13 | 0.250 |
Why?
|
| Histocompatibility Antigens | 1 | 2023 | 12 | 0.250 |
Why?
|
| Metabolic Diseases | 1 | 2023 | 32 | 0.230 |
Why?
|
| Administration, Oral | 1 | 2023 | 212 | 0.230 |
Why?
|
| Fatty Liver | 1 | 2023 | 56 | 0.230 |
Why?
|
| Adolescent | 3 | 2022 | 5035 | 0.230 |
Why?
|
| Immunoglobulin A | 1 | 2022 | 58 | 0.220 |
Why?
|
| Aging | 1 | 2007 | 639 | 0.220 |
Why?
|
| Young Adult | 3 | 2022 | 4012 | 0.210 |
Why?
|
| Tumor Cells, Cultured | 5 | 2016 | 480 | 0.210 |
Why?
|
| Gene Expression Regulation | 1 | 2007 | 968 | 0.210 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2023 | 325 | 0.210 |
Why?
|
| Carrier Proteins | 1 | 2023 | 287 | 0.210 |
Why?
|
| Saliva | 1 | 2022 | 97 | 0.210 |
Why?
|
| Glutathione S-Transferase pi | 2 | 2011 | 10 | 0.200 |
Why?
|
| Immunoglobulin G | 1 | 2022 | 232 | 0.200 |
Why?
|
| Liver Neoplasms | 1 | 2023 | 195 | 0.200 |
Why?
|
| Disease Progression | 5 | 2014 | 580 | 0.200 |
Why?
|
| Sex Characteristics | 1 | 2022 | 213 | 0.190 |
Why?
|
| Mice | 7 | 2023 | 5668 | 0.190 |
Why?
|
| Pseudogenes | 1 | 2000 | 8 | 0.190 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2001 | 121 | 0.180 |
Why?
|
| DNA | 2 | 2022 | 549 | 0.180 |
Why?
|
| Prognosis | 2 | 2019 | 707 | 0.180 |
Why?
|
| Polymerase Chain Reaction | 2 | 2016 | 430 | 0.170 |
Why?
|
| Genetic Markers | 1 | 2018 | 118 | 0.160 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2018 | 68 | 0.160 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 964 | 0.150 |
Why?
|
| Chemokine CXCL5 | 1 | 2016 | 5 | 0.150 |
Why?
|
| Interleukin-5 | 1 | 2016 | 7 | 0.150 |
Why?
|
| Tissue Array Analysis | 1 | 2016 | 65 | 0.140 |
Why?
|
| Hydroxamic Acids | 1 | 2016 | 30 | 0.140 |
Why?
|
| Epithelial Cells | 4 | 2010 | 366 | 0.140 |
Why?
|
| Vitamin D | 1 | 2018 | 176 | 0.140 |
Why?
|
| DNA Primers | 2 | 2007 | 269 | 0.140 |
Why?
|
| Chemokines, CC | 1 | 2016 | 50 | 0.140 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2013 | 18 | 0.130 |
Why?
|
| Drug Design | 2 | 2015 | 154 | 0.130 |
Why?
|
| Animals | 7 | 2023 | 14307 | 0.130 |
Why?
|
| Child | 1 | 2022 | 2875 | 0.130 |
Why?
|
| Transfection | 2 | 2006 | 496 | 0.120 |
Why?
|
| Fibroblast Growth Factor 2 | 2 | 2004 | 41 | 0.120 |
Why?
|
| Female | 8 | 2022 | 19873 | 0.120 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 2333 | 0.120 |
Why?
|
| Glomerular Filtration Rate | 1 | 2014 | 137 | 0.120 |
Why?
|
| Cluster Analysis | 1 | 2013 | 188 | 0.110 |
Why?
|
| DNA Mutational Analysis | 2 | 2004 | 89 | 0.110 |
Why?
|
| Binding Sites | 2 | 2011 | 597 | 0.110 |
Why?
|
| Acetaminophen | 1 | 2011 | 24 | 0.100 |
Why?
|
| Molecular Sequence Data | 3 | 2011 | 1490 | 0.100 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2012 | 89 | 0.100 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2012 | 342 | 0.100 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2014 | 160 | 0.100 |
Why?
|
| Sequence Alignment | 1 | 2011 | 257 | 0.100 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2001 | 53 | 0.100 |
Why?
|
| Base Sequence | 2 | 2011 | 932 | 0.100 |
Why?
|
| Risk Factors | 1 | 2018 | 3414 | 0.090 |
Why?
|
| Health | 1 | 2010 | 28 | 0.090 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 901 | 0.090 |
Why?
|
| Homozygote | 1 | 2009 | 75 | 0.090 |
Why?
|
| Liver | 1 | 2011 | 447 | 0.090 |
Why?
|
| Models, Genetic | 1 | 2009 | 149 | 0.080 |
Why?
|
| Gene Deletion | 1 | 2009 | 156 | 0.080 |
Why?
|
| Lysine | 1 | 2008 | 104 | 0.080 |
Why?
|
| Up-Regulation | 3 | 2004 | 490 | 0.080 |
Why?
|
| Relaxin | 1 | 2007 | 10 | 0.080 |
Why?
|
| Histones | 1 | 2008 | 177 | 0.070 |
Why?
|
| MicroRNAs | 1 | 2011 | 386 | 0.070 |
Why?
|
| In Situ Hybridization | 1 | 2006 | 125 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2005 | 7 | 0.070 |
Why?
|
| Regression Analysis | 1 | 2007 | 429 | 0.070 |
Why?
|
| Cell Movement | 2 | 2007 | 545 | 0.070 |
Why?
|
| Genomic Imprinting | 1 | 2005 | 35 | 0.070 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2006 | 184 | 0.070 |
Why?
|
| Adenocarcinoma | 1 | 2007 | 239 | 0.060 |
Why?
|
| Proteoglycans | 1 | 2004 | 46 | 0.060 |
Why?
|
| Immunohistochemistry | 2 | 2004 | 859 | 0.060 |
Why?
|
| Prostatic Hyperplasia | 1 | 2004 | 33 | 0.060 |
Why?
|
| Lung Neoplasms | 1 | 2008 | 336 | 0.060 |
Why?
|
| Thymidylate Synthase | 1 | 2003 | 3 | 0.060 |
Why?
|
| Methionine | 1 | 2003 | 28 | 0.060 |
Why?
|
| Repressor Proteins | 1 | 2005 | 226 | 0.060 |
Why?
|
| Proteins | 1 | 2005 | 352 | 0.060 |
Why?
|
| Mice, Knockout | 2 | 2003 | 897 | 0.050 |
Why?
|
| Cell Division | 4 | 2004 | 296 | 0.050 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2001 | 2 | 0.050 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2001 | 2 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2023 | 628 | 0.050 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2001 | 26 | 0.050 |
Why?
|
| Survival Rate | 1 | 2001 | 310 | 0.050 |
Why?
|
| Protein Isoforms | 1 | 2001 | 121 | 0.050 |
Why?
|
| Blotting, Southern | 1 | 2000 | 66 | 0.050 |
Why?
|
| Carbon | 1 | 2021 | 95 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2000 | 229 | 0.040 |
Why?
|
| Neoplasms | 1 | 2008 | 1033 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2004 | 756 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2015 | 1149 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2004 | 1802 | 0.030 |
Why?
|
| Translocation, Genetic | 1 | 1995 | 39 | 0.030 |
Why?
|
| Genetic Engineering | 1 | 1995 | 31 | 0.030 |
Why?
|
| Recombination, Genetic | 1 | 1995 | 90 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2015 | 376 | 0.030 |
Why?
|
| Alleles | 2 | 2005 | 284 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2011 | 1300 | 0.030 |
Why?
|
| Obesity | 1 | 2021 | 965 | 0.030 |
Why?
|
| Hydrolysis | 1 | 2012 | 86 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2012 | 81 | 0.030 |
Why?
|
| Biocatalysis | 1 | 2011 | 27 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 2 | 2007 | 1530 | 0.020 |
Why?
|
| Stromal Cells | 2 | 2000 | 45 | 0.020 |
Why?
|
| Recombinant Proteins | 2 | 2000 | 485 | 0.020 |
Why?
|
| Colony-Forming Units Assay | 1 | 2008 | 12 | 0.020 |
Why?
|
| Clone Cells | 1 | 2008 | 46 | 0.020 |
Why?
|
| Genes, Neoplasm | 1 | 2008 | 14 | 0.020 |
Why?
|
| Alkaline Phosphatase | 1 | 2008 | 48 | 0.020 |
Why?
|
| Acetylation | 1 | 2008 | 94 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2008 | 61 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2008 | 71 | 0.020 |
Why?
|
| Microfilament Proteins | 1 | 2008 | 64 | 0.020 |
Why?
|
| Receptors, Peptide | 1 | 2007 | 20 | 0.020 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2007 | 69 | 0.020 |
Why?
|
| Uniparental Disomy | 1 | 2005 | 3 | 0.020 |
Why?
|
| Consensus Sequence | 1 | 2005 | 24 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2007 | 322 | 0.020 |
Why?
|
| Colonic Neoplasms | 1 | 2008 | 181 | 0.020 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2005 | 45 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2007 | 608 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2008 | 1442 | 0.020 |
Why?
|
| Fibroblast Growth Factor 1 | 1 | 2003 | 4 | 0.020 |
Why?
|
| Nucleotides | 1 | 2003 | 33 | 0.010 |
Why?
|
| Fluorouracil | 1 | 2003 | 32 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2004 | 136 | 0.010 |
Why?
|
| Folic Acid | 1 | 2003 | 46 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2003 | 157 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2003 | 298 | 0.010 |
Why?
|
| Fibroblast Growth Factor 10 | 1 | 2000 | 1 | 0.010 |
Why?
|
| Mitogens | 1 | 2000 | 10 | 0.010 |
Why?
|
| Fibroblast Growth Factor 6 | 1 | 2000 | 1 | 0.010 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 4 | 1 | 2000 | 2 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2003 | 562 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2000 | 445 | 0.010 |
Why?
|
| Hypoxanthine Phosphoribosyltransferase | 1 | 1995 | 9 | 0.010 |
Why?
|
| Genes, myc | 1 | 1995 | 28 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 1995 | 49 | 0.010 |
Why?
|
| Genes, Immunoglobulin | 1 | 1995 | 40 | 0.010 |
Why?
|
| Gene Targeting | 1 | 1995 | 39 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 1995 | 154 | 0.010 |
Why?
|
| Plasmids | 1 | 1995 | 233 | 0.010 |
Why?
|
| Stem Cells | 1 | 1995 | 132 | 0.010 |
Why?
|
| Cell Line | 1 | 1995 | 1289 | 0.010 |
Why?
|